Affordable Access

deepdyve-link
Publisher Website

Coût du lupus systémique en France des patients adultes avec une maladie active et traitée (étude LUCIE)

Authors
  • Amoura, Z.
  • Deligny, C.
  • Pennaforte, J.-L.
  • Hamidou, M.
  • Blanco, P.
  • Hachulla, E.
  • Pourrat, J.
  • Queyrel, V.
  • Garofano, A.
  • Maurel, F.
  • Levy-Bachelot, L.
  • Boucot, I.1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  • 1 Service de médecine interne 2, Centre national de référence lupus, hôpital La Pitié-Salpétrière
  • 2 Service de médecine interne et rhumatologie, CHU de Fort-de-France
  • 3 Service de médecine interne, hôpital Robert-Debré
  • 4 Service de médecine interne, hôpital Hôtel-Dieu
  • 5 Service de médecine interne, hôpital Pèllegrin
  • 6 Service de médecine interne, hôpital Huriez
  • 7 Service de néphrologie et immunologie clinique, hôpital Rangueil
  • 8 Service de médecine interne, hôpital l’Archet
  • 9 IMS Real-World Evidence Solutions, Health Economics & Outcomes Research, Tour Ariane
  • 10 GlaxoSmithKline
Type
Published Article
Journal
La Revue de Médecine Interne
Publisher
Elsevier
Publication Date
Jan 01, 2014
Identifiers
DOI: 10.1016/j.revmed.2014.02.001
Source
Elsevier
Keywords
License
Unknown

Abstract

PurposeTo evaluate in France the annual direct medical cost of adult patients with active systemic lupus erythematosus (SLE) on medication and estimate the cost of a flare. MethodsA two-year, observational, retrospective, multicenter study, carried out between December 2010 and February 2011. Patients’ characteristics, SLE disease activity and severity, rate of flares, healthcare consumption (medications, hospitalisations, etc.) were evaluated. Medical costs were assessed from the national Health Insurance perspective. Cost predictors were estimated using multivariate regression models. ResultsEight centres specialized in SLE management included 93 eligible patients (including 50.5% severe). The mean age was 39.9 (11.9) years and 93.5% were women. At baseline, the mean SLE duration was 9.8 (6.6) years. The mean scores of the SELENA-SLEDAI instrument and the SLICC/ACR index were higher in severe patients (9.8 vs 5.6, and 1.2 vs 0.4 respectively; P<0.001). Over the study period, 51% of patients received the combination containing at least corticosteroids or immunosuppressants. The mean annual direct medical cost of severe patients was €4660 versus €3560 for non-severe patients (non-significant difference). The cost of medications (61.8% of the annual cost) was higher in severe patients (€3214 vs €1856; P<0.05). Immunosuppressants and biologics represented 26.5% and 4.6% of the annual total cost respectively. Patients experienced on average 1.10 (0.59) flares/year, of which 0.50 were severe flare. The occurrence of a new severe flare incremented the annual cost of €1330 (P<0.05). ConclusionMedications represented the major component of the annual direct medical cost. Severe flares increase significantly the cost of SLE care management.

Report this publication

Statistics

Seen <100 times